GSK PLC financials
Also U.S.-listed. GSK PLC is also a foreign private issuer filing with the U.S. SEC. View its EDGAR financials: GSK — GSK plc
GSK PLC
Country: GB Reporting currency: GBP Latest annual report: 2025-12-31
LEI:
5493000HZTVUYLO1D793 Financial statements
(GBP, as reported — unscaled; 120 line items across 3 annual periods)
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Income statement | |||
| Cost of sales | £9.02B | £9.05B | £8.56B |
| Gross profit | £23.65B | £22.33B | £21.76B |
| Operating profit (EBIT) | £7.93B | £4.02B | £6.75B |
| Finance costs | £701.0M | £669.0M | £792.0M |
| Profit before tax | £7.40B | £3.48B | £6.06B |
| Income tax expense | £1.11B | £526.0M | £756.0M |
| Profit for the year | £6.29B | £2.95B | £5.31B |
| — attributable to owners | £5.72B | £2.58B | £4.93B |
| — attributable to NCI | £573.0M | £376.0M | £380.0M |
| Total comprehensive income | £6.78B | £2.78B | £4.99B |
| Per share | |||
| Basic EPS | £1.41 | £0.63 | £1.22 |
| Diluted EPS | £1.39 | £0.62 | £1.20 |
| Free cash flow / share | £1.41 | £1.09 | £1.23 |
| Cash flow statement | |||
| Cash generated from operations | £8.94B | £7.86B | £8.10B |
| Net cash from operating activities | £7.74B | £6.55B | £6.77B |
| Net cash from investing activities | -£4.23B | -£1.23B | -£1.59B |
| Purchase of PP&E (capex) | £1.35B | £1.40B | £1.31B |
| Purchase of intangibles | £1.64B | £1.58B | £1.03B |
| Net cash from financing activities | -£3.69B | -£4.73B | -£5.64B |
| Dividends paid | £2.56B | £2.44B | £2.25B |
| Lease liability payments | £241.0M | £226.0M | £197.0M |
| Net change in cash | -£177.0M | £599.0M | -£468.0M |
| Balance sheet | |||
| Total assets | £61.12B | £59.46B | — |
| Non-current assets | £43.61B | £42.47B | — |
| Property, plant & equipment | £9.32B | £9.23B | — |
| Right-of-use assets | £726.0M | £846.0M | — |
| Intangible assets & goodwill | £7.02B | £6.98B | — |
| Current assets | £17.51B | £17.00B | — |
| Inventories | £5.92B | £5.67B | — |
| Trade & other receivables | £7.47B | £6.84B | — |
| Cash & equivalents | £3.40B | £3.87B | £2.94B |
| Total equity | £15.96B | £13.09B | £12.79B |
| — attributable to owners | £16.38B | £13.67B | — |
| Non-controlling interests | -£421.0M | -£585.0M | — |
| Non-current liabilities | £23.77B | £24.68B | — |
| Long-term borrowings | £14.71B | £14.64B | — |
| Current liabilities | £21.39B | £21.70B | — |
| Short-term borrowings | £3.01B | £2.35B | — |
| Trade & other payables | £15.38B | £15.34B | — |
| Deferred tax liabilities | £291.0M | £382.0M | — |
| Derived metrics | |||
| Free cash flow | £6.39B | £5.16B | £5.45B |
| Return on equity | 39.4% | 22.6% | 41.5% |
| Cash conversion ratio | 1.23× | 2.22× | 1.28× |
| Capex coverage | 5.74× | 4.68× | 5.15× |
| Other reported items | |||
| Adjustments For Reconcile Profit Loss | £2.65B | £4.91B | £2.79B |
| Bank Overdrafts Classified As Cash Equivalents | £190.0M | £467.0M | £78.0M |
| Cash and Cash Equivalents If Different From Statement of Financial Position | £3.21B | £3.40B | £2.86B |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | -£27.0M | -£18.0M | £49.0M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | £1.69B | £805.0M | £1.46B |
| Comprehensive Income Attributable To Noncontrolling Interests | £555.0M | £372.0M | £355.0M |
| Comprehensive Income Attributable To Owners of Parent | £6.23B | £2.41B | £4.64B |
| Current Derivative Financial Assets | £121.0M | £109.0M | — |
| Current Derivative Financial Liabilities | £75.0M | £192.0M | — |
| Current Tax Assets | £288.0M | £489.0M | — |
| Current Tax Liabilities | £498.0M | £703.0M | — |
| Decrease Increase Through Tax On Sharebased Payment Transactions | -£31.0M | -£4.0M | -£7.0M |
| Deferred Tax Assets | £6.52B | £6.76B | — |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | £2.56B | £2.44B | £2.25B |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners | £722.0M | £656.0M | £652.0M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | £0.18 | £0.16 | £0.16 |
| Dividends Received From Investments Accounted For Using Equity Method Classified As Investing Activities | £67.0M | £15.0M | £11.0M |
| Dividends Recognised As Distributions To Noncontrolling Interests | £391.0M | £416.0M | £412.0M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -£19.0M | -£54.0M | -£99.0M |
| Finance Income | £169.0M | £122.0M | £115.0M |
| Gains Losses On Cash Flow Hedges Before Tax | -£41.0M | £0 | -£1.0M |
| Gains Losses On Change In Value of Time Value of Options Net of Tax | £4.0M | -£4.0M | £0 |
| Gains Losses On Disposals of Investments | £0 | £6.0M | £1.0M |
| Income Tax Relating To Cash Flow Hedges of Other Comprehensive Income | £2.0M | -£1.0M | -£1.0M |
| Income Tax Relating To Investments In Equity Instruments of Other Comprehensive Income | £20.0M | -£17.0M | -£14.0M |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | £33.0M | £122.0M | £41.0M |
| Income Taxes Paid Refund Classified As Operating Activities | £1.20B | £1.31B | £1.33B |
| Increase Decrease Through Disposal of Subsidiary | — | -£2.0M | — |
| Increase Decrease Through Sharebased Payment Transactions | £374.0M | £344.0M | £307.0M |
| Intangible Assets Other Than Goodwill | £16.75B | £15.52B | — |
| Interest Paid Classified As Financing Activities | £679.0M | £632.0M | £766.0M |
| Interest Received Classified As Investing Activities | £154.0M | £138.0M | £115.0M |
| Investment Accounted For Using Equity Method | £89.0M | £96.0M | — |
| Issue of Equity | £15.0M | £20.0M | £10.0M |
| Issued Capital | £1.35B | £1.35B | — |
| Liabilities | £45.16B | £46.38B | — |
| Liabilities Included In Disposal Groups Classified As Held For Sale | £139.0M | £0 | — |
| Net Assets Liabilities | £15.96B | £13.09B | — |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | £300.0M | £3.0M | — |
| Noncurrent Derivative Financial Assets | £0 | £1.0M | — |
| Noncurrent Derivative Financial Liabilities | £67.0M | £0 | — |
| Noncurrent Financial Liabilities At Fair Value Through Profit Or Loss | £5.38B | £6.11B | — |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | £1.04B | £1.10B | — |
| Noncurrent Provisions For Employee Benefits | £1.69B | £1.86B | — |
| Other Cash Payments To Acquire Equity Or Debt Instruments of Other Entities Classified As Investing Activities | £92.0M | £103.0M | £123.0M |
| Other Cash Receipts From Sales of Equity Or Debt Instruments of Other Entities Classified As Investing Activities | £189.0M | £2.36B | £1.83B |
| Other Comprehensive Income | £493.0M | -£173.0M | -£317.0M |
| Other Comprehensive Income Before Tax Gains Losses From Investments In Equity Instruments | £215.0M | -£100.0M | -£244.0M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | £133.0M | £506.0M | £71.0M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | £216.0M | -£478.0M | -£52.0M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | £277.0M | £305.0M | -£265.0M |
| Other Inflows Outflows of Cash Classified As Financing Activities | £46.0M | £129.0M | £334.0M |
| Other Longterm Provisions | £610.0M | £589.0M | — |
| Other Noncurrent Assets | £2.15B | £1.94B | — |
| Other Noncurrent Liabilities | £1.02B | £1.10B | — |
| Other Operating Income Expense | £16.0M | -£1.53B | -£363.0M |
| Other Reserves | £1.32B | £1.05B | — |
| Other Shortterm Provisions | £938.0M | £1.95B | — |
| Payments To Acquire Or Redeem Entitys Shares | £1.38B | £0 | £0 |
| Proceeds From Contributions of Noncontrolling Interests | £0 | £9.0M | £7.0M |
| Proceeds From Issuing Shares | £15.0M | £20.0M | £10.0M |
| Proceeds From Noncurrent Borrowings | £1.98B | £1.07B | £223.0M |
| Proceeds From Sales of Intangible Assets Classified As Investing Activities | £115.0M | £131.0M | £12.0M |
| Proceeds From Sales of Investments Accounted For Using Equity Method | £0 | £0 | £1.0M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | £24.0M | £65.0M | £28.0M |
| Purchase of Interests In Investments Accounted For Using Equity Method | £0 | £43.0M | £0 |
| Purchase of Treasury Shares | £1.38B | — | — |
| Reclassification Adjustments On Cash Flow Hedges Net of Tax | -£36.0M | -£4.0M | -£4.0M |
| Repayments of Noncurrent Borrowings | £1.40B | £1.61B | £2.26B |
| Research and Development Expense | £7.53B | £6.40B | £6.22B |
| Retained Earnings | £10.21B | £7.80B | — |
| Revenue From Royalties | £879.0M | £639.0M | £953.0M |
| Revenue From Sale of Goods | £32.67B | £31.38B | £30.33B |
| Selling General and Administrative Expense | £9.09B | £11.02B | £9.38B |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | £1.0M | -£3.0M | -£5.0M |
| Share Premium | £3.50B | £3.47B | — |
Methodology
Every line item above is a fact tagged in GSK PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.